Industry veteran in oncology antibody discovery & development Dr Haijun Sun appointed Chief Scientific Officer Expansion of the Scientific Advisory Board with appointments of leading experts in preclinical, translational and clinical drug development Barcelona, Spain, 21 October 2021: ONA Therapeutics (“ONA”), which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism in […]
Funds will be used to support the development of pioneering mammary biotechnology to bring a novel infant feeding option to market that better meets infants’ nutritional needs Syndicate includes leading clean tech and food tech investors Copenhagen, Denmark – 20 October 2021 – Novo Holdings, a leading international life science investor, today announces it has led […]
October 18, 2021 Early data from Phase 1/2 clinical trial in pediatric patients with methylmalonic acidemia showed measurable levels of a biomarker indicating site-specific gene insertion and protein expression Based on safety data from first two patients, independent Data Safety Monitoring Board recommended continuation of trial, enabling enrollment of children as young as six months […]
CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients, today announced the pricing of its upsized initial public offering of 10,500,000 shares of common stock at an initial public offering price of $16.00 […]
LONDON, 18 October 2021: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces a number of developments. Over the past six months Arix has worked to position the Company for the future which has involved a number of strategic […]
